Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
Phase 3
Completed
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 17609
- Registration Number
- NCT03574597
- Locations
- 🇺🇸
Mercy Hospital and Medical Center, Chicago, Illinois, United States
🇺🇸Preferred Primary Care Physicians Inc., Pittsburgh, Pennsylvania, United States
🇺🇸Angel City Research, Inc., Los Angeles, California, United States
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisordersOverweight or Obesity
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT03574584
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Lincoln, Nebraska, United States
A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 758
- Registration Number
- NCT03560336
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Yangsan, Korea, Republic of
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
Phase 3
Completed
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo I (Semaglutide)Drug: Placebo II (Semaglutide)
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1210
- Registration Number
- NCT03552757
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Phase 3
Completed
- Conditions
- Overweight or ObesityMetabolism and Nutrition Disorder
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1961
- Registration Number
- NCT03548935
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Taunton, United Kingdom
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Phase 3
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 902
- Registration Number
- NCT03548987
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Odesa, Ukraine
A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 160
- Registration Number
- NCT03528551
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 105
- Registration Number
- NCT03479762
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Soeborg, Denmark
A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 57
- Registration Number
- NCT03479892
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT03466567
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath